Last reviewed · How we verify
Continuation of spironolactone
At a glance
| Generic name | Continuation of spironolactone |
|---|---|
| Sponsor | Asan Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment (PHASE4)
- Therapy to Maintain Remission in Dilated Cardiomyopathy (NA)
- Pilot Study on Withdrawal of Spironolactone Among Heart Failure With Improved Ejection Fraction (NA)
- Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Continuation of spironolactone CI brief — competitive landscape report
- Continuation of spironolactone updates RSS · CI watch RSS
- Asan Medical Center portfolio CI